Actively Recruiting
STunning in Acute Myocardial Infarction - BAS
Led by Vastra Gotaland Region · Updated on 2025-06-27
120
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)
CONDITIONS
Official Title
STunning in Acute Myocardial Infarction - BAS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with STEMI who undergo primary PCI within 6 hours of symptom onset (Excluding prodromal symptoms)
- Provided informed consent
- Age 18 years or older
You will not qualify if you...
- Killip class 3 or higher
- Chronic kidney disease with GFR less than 25 ml/min/1.73 m2
- Pre-existing non-reversible cardiac dysfunction or heart failure
- Current treatment with any beta blocker, RAAS inhibitor, or SGLT2 inhibitor
- Contraindications to study drugs that risk patient safety as assessed by the treating physician
- Life expectancy less than one year
- Pregnancy or women of childbearing potential not sterilized or not using medically accepted contraception
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sahlgrenska University Hospital
Gothenburg, Sweden, 41345
Actively Recruiting
Research Team
B
Björn Redfors, Professor
CONTACT
M
Margareta Scharin Täng, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here